Par Pharmaceutical
Executive Summary
Former Bristol-Myers exec John Hoofnagle named VP-operations, and retired Public Health Service Quality Control Director Sydney Hamet named director of compliance for the firm, which has been a target of the ongoing generic drug investigation.